NASDAQ:CUR Neuralstem (CUR) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free CUR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.37▼$0.4050-Day Range$0.67▼$1.5252-Week Range$1.10▼$13.78Volume173,299 shsAverage Volume236,278 shsMarket Capitalization$830,130.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Neuralstem alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Neuralstem Stock (NASDAQ:CUR)Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert CUR Stock News HeadlinesNovember 25, 2023 | lse.co.ukAguas Da Curia Share Price (CUR.LS)August 22, 2023 | seekingalpha.comXAUUSD:CUR Gold Spot PriceMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJuly 20, 2023 | thestreet.com4 Biotech Stocks Under $10 Moving HigherJune 28, 2023 | seekingalpha.comXPTUSD:CUR Platinum Spot PriceMay 16, 2023 | seekingalpha.comXAUUSD:CUROctober 20, 2022 | marketscreener.comNovAccess Global : Announces Fireside Chat with Board Member Perspectives - Marketscreener.comOctober 12, 2022 | news.yahoo.comAnti-inflammatory compound supercharges stem cell stroke treatment - Yahoo NewsMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.October 11, 2022 | businessinsider.comBest microscope photos of 2022 reveal stunning hidden world around us - Business InsiderOctober 11, 2022 | benzinga.comStem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - BenzingaOctober 6, 2022 | globenewswire.comAruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit - GlobeNewswireSeptember 16, 2022 | streetinsider.comBOLDEN THERAPEUTICS RECEIVES $406,466 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS - StreetInsider.comSeptember 2, 2022 | prnewswire.comBGI-led Research Builds the World's First Spatiotemporal Map of Brain Regeneration - PR NewswireAugust 23, 2022 | globenewswire.comGlobal Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight - GlobeNewswireAugust 23, 2022 | newsweek.comHow Scientists Successfully Reversed Alzheimer's in Mice - NewsweekAugust 22, 2022 | techcrunch.comDioseve wants to help infertile people with tech that grows egg cells - TechCrunchAugust 12, 2022 | finance.yahoo.comThe Global Stem Cell Manufacturing Market grew USD 4,378.00 million by 2027, at a CAGR of 12.23%. - Yahoo FinanceAugust 12, 2022 | globenewswire.comThe Global Stem Cell Manufacturing Market grew USD 4,378.00 - GlobeNewswireAugust 4, 2022 | finance.yahoo.comCalidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma - Yahoo FinanceAugust 2, 2022 | businesswire.comCalidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma - Business WireAugust 1, 2022 | in.investing.comHow chickenpox virus is linked to onset of Alzheimer's disease - Investing.com IndiaJuly 21, 2022 | forbes.comCan Inflammation Lead To Cognitive Issues? Past Research Says 'Yes', With Implications For Covid-19 - ForbesJuly 17, 2022 | abcnews.go.comHigh-flying experiment: Do stem cells grow better in space? - ABC NewsJuly 12, 2022 | streetinsider.comjCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer - StreetInsider.comJuly 11, 2022 | forbes.comResearch On Flies Provides Hope For Brain Repair - ForbesJuly 7, 2022 | finance.yahoo.comStem Cell Assays Market Report 2022-2027: Government Initiatives to Boost Stem Cell Research Present Opportunities - Yahoo FinanceSee More Headlines Receive CUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuralstem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CUR CUSIPN/A CIK1357459 Webwww.neuralstem.com Phone301-366-4841FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,930,000.00 Net Margins-39,417.64% Pretax MarginN/A Return on Equity-170.51% Return on Assets-110.16% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual Sales$260,000.00 Price / Sales3.19 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.06Miscellaneous Outstanding Shares2,100,000Free FloatN/AMarket Cap$830,130.00 OptionableNot Optionable Beta1.81 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Kenneth C. Carter (Age 59)Exec. Chairman, CEO & Principal Financial Officer Dr. Karl Y. Johe (Age 59)Co-Founder Dr. Thomas G. Hazel Ph.D.Sr. VP of ResearchDr. David P. Recker (Age 61)Chief Medical Officer Key CompetitorsScinai ImmunotherapeuticsNASDAQ:SCNITC BiopharmNASDAQ:TCBPSQZ BiotechnologiesNYSE:SQZWindtree TherapeuticsNASDAQ:WINTEloxx PharmaceuticalsNASDAQ:ELOXView All Competitors CUR Stock Analysis - Frequently Asked Questions How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.45) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. Neuralstem had a negative trailing twelve-month return on equity of 170.51% and a negative net margin of 39,417.64%. When did Neuralstem's stock split? Neuralstem shares reverse split before market open on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), ACADIA Pharmaceuticals (ACAD), Athersys (ATHX), Caladrius Biosciences (CLBS), Rexahn Pharmaceuticals (REXN) and This page (NASDAQ:CUR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.